By Counterforce Health Team in Tepezza (teprotumumab) —

How to Get Tepezza (teprotumumab) Covered by Aetna CVS Health in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Tepezza Approved by Aetna CVS Health in New Jersey

Aetna CVS Health requires prior authorization for Tepezza (teprotumumab-trbw, J-code J3241) to treat moderate-to-severe thyroid eye disease in adults 18+. Coverage is limited to one lifetime course of 8 infusions over 24 weeks. First step: Have your ophthalmologist submit documentation showing Clinical Activity Score ≥4, euthyroid status, and prior steroid failure via Aetna's provider portal or the Tepezza precertification form. If denied, New Jersey offers robust external review through the Independent Health Care Appeals Program (IHCAP) managed by Maximus Federal Services.

Quick action: Download the Tepezza precertification form and schedule your TED specialist evaluation today.

Table of Contents

  1. Plan Types & Coverage Implications
  2. Formulary Status & Tier Placement
  3. Prior Authorization Requirements
  4. Step-by-Step: Fastest Path to Approval
  5. Common Denial Reasons & Solutions
  6. Appeals Process in New Jersey
  7. Cost-Share Dynamics
  8. Specialty Pharmacy Coordination
  9. FAQ
  10. Sources & Further Reading

Plan Types & Coverage Implications

Aetna CVS Health operates several plan types in New Jersey, each with different coverage rules for Tepezza:

Commercial Plans (Fully Insured)

  • HMO/PPO/EPO plans require specialist referrals for ophthalmology
  • Subject to New Jersey external review rights through IHCAP
  • Covered under medical benefit (not pharmacy)

Aetna Better Health (New Jersey Medicaid)

  • Requires ophthalmologist prescription or consultation
  • Age 18+ requirement with moderate-to-severe TED diagnosis
  • 6-month authorization periods

Medicare Advantage

  • Follows Medicare Part B coverage rules
  • Different appeal timelines (72 hours expedited, 14 days standard)

Self-Insured Employer Plans

  • Follow Aetna policies but not subject to New Jersey external review
  • Appeals go through federal ERISA process

Formulary Status & Tier Placement

Tepezza appears on Aetna's 2026 precertification list but is not on the exclusion drug list, meaning it's covered when criteria are met. The medication:

  • Requires precertification regardless of plan type
  • Distributed through CVS Specialty Pharmacy
  • Billed under medical benefit using J-code J3241
  • No automatic formulary tier (case-by-case exception review)

Alternative Agents on Formulary:

  • IV methylprednisolone (first-line, requires trial/failure)
  • Oral corticosteroids
  • Conservative management (lubricants, prism glasses)

Prior Authorization Requirements

Aetna requires comprehensive documentation meeting specific clinical criteria:

Coverage at a Glance

Requirement Details Documentation Needed Source
Age 18+ years Date of birth verification Aetna Policy
Diagnosis Moderate-to-severe TED Clinical Activity Score ≥4, orbital photos Aetna Policy
Thyroid Status Euthyroid or stable TSH, FT4, FT3 within 30 days Aetna Policy
Prior Therapy Steroid trial/failure Treatment records, contraindications Aetna Policy
Prescriber Ophthalmologist/endocrinologist NPI, specialty verification Aetna Policy
Course Limit One lifetime (8 infusions) No prior Tepezza treatment Aetna Policy

Required Clinical Documentation

Thyroid Eye Disease Severity:

  • Clinical Activity Score (CAS) ≥4 out of 10
  • Proptosis measurements in millimeters
  • High-quality orbital photographs showing inflammation
  • Functional impact documentation (diplopia, vision changes)

Prior Treatment History:

  • IV methylprednisolone trial (typically 500mg weekly × 6 weeks, then 250mg weekly × 6 weeks)
  • Documentation of inadequate response or contraindications
  • Selenium supplementation trial (if applicable)
  • Conservative management attempts

Laboratory Requirements:

  • TSH, free T4, free T3 within 30 days
  • Levels within 50% of normal limits
  • Diabetes monitoring if applicable (Tepezza can worsen hyperglycemia)

Step-by-Step: Fastest Path to Approval

1. Specialist Evaluation (Week 1)

Who: Patient schedules with in-network ophthalmologist Action: Complete TED assessment including CAS scoring, proptosis measurements, orbital photography Timeline: 1-2 weeks for appointment

2. Gather Documentation (Week 2)

Who: Clinic staff coordinates records Documents: Prior steroid trials, thyroid function tests, treatment failure documentation Timeline: 3-5 business days

3. Submit Prior Authorization (Week 2-3)

Who: Ophthalmologist or staff Method: Aetna provider portal (preferred) or Tepezza precertification form Timeline: Same-day electronic submission

4. Track Submission (Week 3)

Who: Clinic staff Action: Confirm receipt within 3 days, obtain reference number Follow-up: Weekly status checks via portal or phone (1-866-752-7021)

5. Response & Next Steps (Week 4-5)

Standard review: 15-30 business days Expedited review: 72 hours (if serious health risk documented) If approved: CVS Specialty coordinates infusion scheduling

6. Appeal if Denied (Week 5+)

Internal appeal: Within 180 days of denial External review: After internal appeal completion Timeline: 45 days for IHCAP decision

7. Treatment Coordination (Post-Approval)

Who: CVS Specialty Pharmacy (1-800-250-9631) Action: Schedule 8 infusions over 24 weeks Site: Outpatient infusion center or physician office

Common Denial Reasons & Solutions

Denial Reason How to Overturn Required Documentation
Insufficient TED severity Submit updated CAS ≥4, new orbital photos Clinical reassessment by ophthalmologist
Missing prior therapy Document steroid trial/failure or contraindications Treatment records, adverse event documentation
Non-euthyroid status Provide recent thyroid function tests TSH, FT4, FT3 within 30 days showing stability
Experimental use Emphasize FDA-approved TED indication FDA labeling, clinical guidelines
Lifetime limit exceeded Exceptional circumstances only Peer-reviewed evidence of disease progression
From our advocates: We've seen cases where initial denials for "insufficient documentation" were quickly overturned when providers resubmitted with complete orbital photographs and detailed CAS scoring. The key is addressing the specific denial reason with targeted evidence rather than repeating the same incomplete submission.

Appeals Process in New Jersey

New Jersey offers one of the most comprehensive external review systems in the country through the Independent Health Care Appeals Program (IHCAP).

Internal Appeals (First Step)

Timeline: 180 days from denial notice Method: Aetna provider portal or written appeal Decision: 30-45 days (standard), 72 hours (expedited) Required: Detailed medical necessity letter addressing denial reasons

External Review via IHCAP

Eligibility: After completing internal appeals for fully insured plans Timeline: 4 months (180 days) from final internal denial Submission: Directly to Maximus Federal Services (contracted by New Jersey) Cost: Free to patient/provider Decision: 45 days, binding on insurer

IHCAP Process:

  1. Preliminary review (5 business days) to confirm eligibility
  2. Physician panel review with TED specialty expertise
  3. Consideration of medical records, clinical guidelines, FDA labeling
  4. Binding decision requiring insurer compliance

Contact Information:

  • IHCAP Hotline: 1-888-393-1062
  • New Jersey DOBI Consumer Hotline: 1-800-446-7467

Success Factors for Appeals

  • Address specific denial reasons point-by-point
  • Include peer-reviewed literature supporting TED treatment
  • Provide detailed medical necessity letter from specialist
  • Submit complete documentation package
  • Meet all deadlines

Counterforce Health specializes in turning insurance denials into evidence-backed appeals by analyzing denial letters, plan policies, and clinical notes to draft targeted rebuttals aligned with payer-specific rules. Their platform helps identify the exact denial basis and weaves together the right citations—FDA labeling, peer-reviewed studies, and clinical guidelines—with required clinical facts to create compelling appeals.

Cost-Share Dynamics

Tepezza costs approximately $350,000-$500,000 for a complete 8-infusion course. Under Aetna CVS Health medical benefit coverage:

Typical Patient Responsibility:

  • Deductible application (if not met)
  • 20% coinsurance after deductible
  • Out-of-pocket maximum protection

Cost Support Options:

  • Amgen By Your Side copay assistance program
  • Patient assistance programs for qualifying individuals
  • Hospital charity care programs in New Jersey

Specialty Pharmacy Coordination

CVS Specialty Pharmacy manages Tepezza distribution and coordination:

Setup Process:

  1. Prior authorization approval triggers CVS Specialty outreach
  2. Patient enrollment and insurance verification
  3. Infusion site coordination and scheduling
  4. Ongoing clinical monitoring and support

Contact: 1-800-250-9631 for CVS Specialty services

FAQ

Q: How long does Aetna CVS Health prior authorization take in New Jersey? A: Standard review takes 15-30 business days. Expedited review (for serious health risk) is completed within 72 hours.

Q: What if Tepezza is non-formulary on my plan? A: Tepezza requires case-by-case exception review but is not excluded. Submit prior authorization with complete clinical documentation.

Q: Can I request an expedited appeal? A: Yes, if delay would cause serious harm to health or function. Document the urgency with clinical evidence.

Q: Does step therapy apply if I failed steroids outside New Jersey? A: Yes, prior treatment failures from any location count toward meeting Aetna's step therapy requirements.

Q: What happens if I need retreatment after 8 infusions? A: Aetna considers members ineligible for repeat courses. Exceptional circumstances require peer-reviewed evidence and peer-to-peer review.

Q: How do I verify my plan's specific requirements? A: Call Aetna member services at 1-800-ASK-AETNA or check your member portal for formulary and precertification requirements.

For patients and providers navigating complex prior authorization requirements, Counterforce Health offers specialized support in converting insurance denials into successful appeals through targeted, evidence-based documentation that aligns with each payer's specific policies and requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and appeal procedures may vary by plan and change over time. Always verify current requirements with your insurance plan and consult healthcare providers for medical decisions. For assistance with appeals and prior authorization documentation, contact your provider or consider specialized services like Counterforce Health.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.